Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.

被引：6
|
作者：
Chang, Sam S.
Chamie, Karim
Gonzalgo, Mark L.
Kramolowsky, Eugene V.
Sexton, Wade J.
Reddy, Sandeep K.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.431
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
431
引用
收藏
页数：3
相关论文
共 7 条
  • [1] Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
    Chamie, Karim
    Chang, Sam S.
    Gonzalgo, Mark
    Kramolowsky, Eugene V.
    Sexton, Wade J.
    Bhar, Paul
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
    Chamie, Karim
    Lee, John H.
    Rock, Amy
    Rhode, Peter R.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase II/III clinical results of IL-15R[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
    Chamie, Karim
    Chang, Sam
    Gonzalgo, Mark L.
    Kramolowsky, Eugene, V
    Sexton, Wade J.
    Reddy, Sandeep K.
    Bhar, Paul
    Garner, Chad
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RAFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS
    Chang, Sam
    Chamie, Karim
    Hidalgo, Mark
    Kramolowsky, Eugene
    Sexton, Wade
    Reddy, Sandeep
    Soon-Shiong, Patrick
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1047 - E1047
  • [5] PHASE 2/3 CLINICAL RESULTS OF IL-15RAFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS.
    Chamie, Karim
    Chang, Sam
    Gonzalgo, Mark
    Kramolowski, Eugene
    Reddy, Sandeep
    Soon-Shiong, Patrick
    Garner, Chad
    JOURNAL OF UROLOGY, 2021, 206 : E120 - E121
  • [6] Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RaFc superagonist N-803 plus BCG.
    Chamie, Karim
    Chang, Sam S.
    Kramolowsky, Eugene V.
    Gonzalgo, Mark L.
    Lechpammer, Stanislav
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial
    Boorjian, Stephen A.
    Dinney, Colin P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
1